期刊
SLEEP MEDICINE
卷 6, 期 5, 页码 467-470出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.sleep.2005.02.003
关键词
sleep; sleep apnea syndrome; obstructive sleep apnea; sibutramine; obesity; drug adverse effects; anti-obesity agents; drug safety
Background: As any drug acting on the central nervous system, sibutramine might worsen obstructive sleep apnea-hypopnea syndrome (OSAHS). This study aims to assess the risk of administering sibutramine to patients with OSAHS. Methods: We screened male, symptomatic OSAHS patients who presented consecutively at the sleep clinic. Twenty-one subjects were included, aged between 30 and 60 years, body mass index between 25 and 35 kg/m(2) and apnea-hypopnea index (AHI) greater than 10 AH/h. Intervention was administration of 15 mg sibutramine (SB) or placebo (PL), at bedtime, for 1 month. Each patient underwent overnight polysomnograms both before entering the study and after 1 month. Outcome measures were AHI and sleep efficiency (SE). Results: Two patients withdrew prematurely, one due to headache, a possible side effect. Results are from 10 patients in the SB group and nine in the PL group. No significant differences were seen in any of the groups before or after treatment in measures of SE, respiratory disturbance, body weight, blood pressure, cardiac or respiratory frequency. Significant reduction occurred in the amount of REM sleep, from 19 to 13% (P=0.04) in SB group and in Epworth sleepiness score in PL and SB groups. Conclusion: The results indicate that sibutramine does not worsen sleep or breathing during sleep in patients with OSAHS. (c) 2005 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据